<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151219">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01727089</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02206</org_study_id>
    <secondary_id>NCI-2012-02206</secondary_id>
    <secondary_id>PHII-121</secondary_id>
    <secondary_id>9144</secondary_id>
    <secondary_id>N01CM00099</secondary_id>
    <secondary_id>N01CM00039</secondary_id>
    <secondary_id>N01CM00038</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <nct_id>NCT01727089</nct_id>
  </id_info>
  <brief_title>Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase II Study of Bevacizumab Alone or in Combination With TRC 105 for Advanced Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well bevacizumab with or without monoclonal
      antibody therapy works in treating patients with metastatic kidney cancer. Monoclonal
      antibodies, such as bevacizumab and anti-endoglin monoclonal antibody TRC105, can block
      tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
      Others find tumor cells and help kill them or carry tumor-killing substances to them.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the progression-free survival at 12 and 24 weeks for bevacizumab alone or in
      combination with TRC105 (anti-endoglin monoclonal antibody TRC105).

      SECONDARY OBJECTIVES:

      I. Toxicity and Response Evaluation Criteria in Solid Tumors (RECIST) response rate for the
      combination compared to single agent bevacizumab.

      TERTIARY OBJECTIVES:

      I. To evaluate tumor tissue expression of endoglin (CD105), transforming growth factor, beta
      receptor II (TGFBR2), activin A receptor type II-like 1 (ACVRL1) and transforming growth
      factor, beta receptor 1 (TGFBR1) kinase from pre- and post-treatment tissue samples in order
      to determine whether CD105 and stem cell activation occurs after exposure to anti-vascular
      endothelial growth factor (VEGF) therapy as predicted by laboratory models, and whether
      exposure to anti-endoglin monoclonal antibody TRC105 affects these changes.

      II. A primary goal of tissue analysis will be to generate preliminary data to correlate
      levels of CD105, TGFBR2, ACVRL1 and TGFBR1 in tissue with response to bevacizumab in
      combination with anti-endoglin monoclonal antibody TRC105 compared to bevacizumab alone.

      III. To compare the soluble CD105 levels at baseline and after treatment between the group
      receiving bevacizumab alone and the group receiving bevacizumab in combination with
      anti-endoglin monoclonal antibody TRC105.

      IV. To compare TGFBR2 levels at baseline and after treatment between the group receiving
      bevacizumab alone and the group receiving bevacizumab in combination with anti-endoglin
      monoclonal antibody TRC105.

      V. To evaluate whether circulating tumor cells (CTCs) can be detected in this patient
      population using parylene membrane filter technology, and whether changes in CTC counts and
      CD105 expression on CTCs during therapy correspond to imaging and clinical response.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15.

      ARM II: Patients receive bevacizumab as in arm 1 and anti-endoglin monoclonal antibody
      TRC105 IV over 1-4 hours on days 1, 8, 15, and 22.

      In both arms, treatment repeats every 28 days for up to 12 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study therapy, patients are followed for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>The duration of time from start of treatment to time of progression or death, assessed at 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Planning is based on the supposition of 12-week PFS of 61% on the control arm and 78% on the combination arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>The duration of time from start of treatment to time of progression or death, assessed at 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The corresponding hypothesized PFS at 24 weeks would be 37% on the single-agent arm and 60% on the combination arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate assessed by RECIST</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AE) and toxicity of study treatment</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The descriptions and grading scales found in the revised National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in CD105 expression</measure>
    <time_frame>Baseline to week 13</time_frame>
    <safety_issue>No</safety_issue>
    <description>Generalized linear models for ordered categorical data will be used to address the treatment and staining interaction using the full dataset.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in TGFbeta-R2 expression</measure>
    <time_frame>Baseline to week 13</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in TGFBR1 expression</measure>
    <time_frame>Baseline to week 13</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Activin A receptor type II-like 1 (ACVRL1) expression</measure>
    <time_frame>Baseline to week 13</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Recurrent Renal Cell Cancer</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <condition>Type 1 Papillary Renal Cell Carcinoma</condition>
  <condition>Type 2 Papillary Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (bevacizumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab as in arm 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-endoglin monoclonal antibody TRC105</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)</arm_group_label>
    <other_name>TRC105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed renal cancer; all
             histologic subtypes will be eligible

          -  Patients must have metastatic disease which is measurable, defined as at least one
             lesion that can be accurately measured in at least one dimension (longest diameter to
             be recorded for non-nodal lesions and short axis for nodal lesions) to &gt;= 20 mm in
             the long axis by chest x-ray, &gt;= 10 mm in the long axis by spiral computed tomography
             (CT), magnetic resonance imaging (MRI), calipers, or clinical exam, or &gt;= 15 mm in
             the short axis for lymph nodes

          -  Patients must have received at least 1 prior systemic therapy for renal cancer but no
             more than 4 prior therapies; they must have documented intolerance to or progression
             despite at least 1 systemic therapy; therapy administered in the adjuvant setting
             counts toward the prior systemic therapy total; if adjuvant therapy is the patient's
             only prior therapy the disease must have recurred during treatment or within 3 months
             of discontinuation

          -  Allowable prior therapies include VEGF tyrosine kinase inhibitor (TKIs), mammalian
             target of rapamycin (mTOR) inhibitors, and cytokine therapy (example: interleukin-2
             [IL2])

          -  At least 2 weeks must have elapsed from the last dose of the prior systemic therapy
             for biologics and 4 weeks for chemotherapy (6 weeks for nitrosoureas or mitomycin C);
             also note that at least 3 weeks should have elapsed since prior TKI administration

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Life expectancy of greater than 6 months

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin within normal institutional limits (except for Gilbert's)

          -  Aspartate aminotransferase (AST) (serum glutamic oxalo-acetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2.5 X institutional upper limit of normal (except subjects with liver metastases,
             who can have AST/ALT =&lt; 5 x ULN)

          -  Creatinine glomerular filtration rate (GFR) (calculated or measured) &gt; 50 mL/min

          -  Hemoglobin &gt;= 9 g/dL

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and
             for the duration of study participation

          -  Should a woman become pregnant or suspect she is pregnant while she or her partner is
             participating in this study, she should inform her treating physician immediately

          -  Men treated or enrolled on this protocol must also agree to use adequate
             contraception prior to the study, for the duration of study participation, and 6
             months after completion of TRC105 or bevacizumab administration

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had systemic biologic therapy or radiotherapy within 2 weeks prior
             to entering the study or those who have not recovered from adverse events related to
             their prior therapy

          -  Patients who have previously been treated with bevacizumab

          -  Patients who have previously been treated with TRC105

          -  Patients who are receiving any other investigational agents

          -  Known central nervous system (CNS) disease except for treated brain metastasis;
             treated brain metastases are defined as having no ongoing requirement for steroids
             and no evidence of progression or hemorrhage after treatment for at least 3 months,
             as ascertained by clinical examination and brain imaging (MRI or CT) (stable dose of
             anticonvulsants are allowed); treatment for brain metastases may include whole brain
             radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, linear accelerator [LINAC], or
             equivalent) or a combination as deemed appropriate by the treating physician;
             patients with CNS metastases treated by neurosurgical resection or brain biopsy
             performed within 3 months prior to day 1 will be excluded

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to TRC105 or bevacizumab

          -  Patients on full-dose anticoagulation will be excluded due to the risk of bleeding;
             antiplatelet therapy will not be exclusionary

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, unhealed wound, gastrointestinal fistula, symptomatic congestive heart
             failure, unstable angina pectoris, myocardial infarction, cerebrovascular accident

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother wishes to participate in the study

          -  Patients with a history of bleeding diathesis or inherited coagulopathy are excluded;
             in addition, those with a history of deep vein thrombosis (DVT) or pulmonary embolus
             within 1 year and still requiring active anticoagulation will be excluded; those with
             a more remote history of DVT or pulmonary embolus may be eligible but the risk of
             recurrent thrombosis should be considered

          -  Patients with history of hereditary hemorrhagic telangiectasis (HHT-1 and HHT-2)

          -  Serious or non-healing wound, ulcer, or bone fracture OR history of abdominal
             fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months
             prior to day 1

          -  Invasive procedures defined as follows:

               -  Major surgical procedure, open biopsy or significant traumatic injury within 28
                  days prior to day 1 therapy

               -  Anticipation of need for major surgical procedures during the course of the
                  study

               -  Core biopsy within 7 days prior to day 1 therapy

          -  Patients with clinically significant cardiovascular disease are excluded:

               -  Inadequately controlled hypertension (HTN) (systolic blood pressure [SBP] &gt;
                  160mmHg and/or diastolic blood pressure [DBP] &gt; 90 mmHg despite antihypertensive
                  medication)

               -  History of cardiovascular accident (CVA) within 6 months

               -  Myocardial infarction or unstable angina within 6 months

               -  New York heart association grade II or greater congestive heart failure

               -  Serious and inadequately controlled cardiac arrhythmia

               -  Significant vascular disease (e.g. aortic aneurysm, history of aortic
                  dissection)

               -  Clinically significant peripheral vascular disease

          -  Patients with known hypersensitivity to Chinese hamster ovary cell products or other
             recombinant human antibodies

          -  Patients with psychiatric illness/social situations that would limit compliance with
             study requirements will be excluded
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Dorff</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beckman Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumanta K. Pal</last_name>
      <phone>626-256-4673</phone>
      <email>spal@coh.org</email>
    </contact>
    <investigator>
      <last_name>Sumanta K. Pal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya B. Dorff</last_name>
      <phone>323-865-3900</phone>
      <email>dorff@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Tanya B. Dorff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Group Inc</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen C. Koehler</last_name>
      <phone>626-396-2900</phone>
      <email>Skoehler@cohmg.com</email>
    </contact>
    <investigator>
      <last_name>Stephen C. Koehler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primo N. Lara</last_name>
      <phone>916-734-3771</phone>
      <email>primo.lara@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Primo N. Lara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado at Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas W. Flaig</last_name>
      <phone>303-724-3888</phone>
      <email>Thomas.glaig@ucdnever.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas W. Flaig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime R. Merchan</last_name>
      <phone>305-243-0865</phone>
      <email>jmerchan@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Jaime R. Merchan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayer N. Fishman</last_name>
      <phone>813-745-8343</phone>
      <email>mayer.fishman@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Mayer N. Fishman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter M. Stadler</last_name>
      <phone>773-702-4150</phone>
      <email>wstadler@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Walter M. Stadler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-6600</phone>
      <email>JLWADE3@sbcglobal.net</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kellogg Cancer Center-Glenview</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britt E. Hanson</last_name>
      <phone>847-503-1000</phone>
      <email>bhanson@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Britt E. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark F. Kozloff</last_name>
      <phone>708-915-6119</phone>
      <email>mfkozloff@aol.com</email>
    </contact>
    <investigator>
      <last_name>Mark F. Kozloff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sreenivasa R. Nattam</last_name>
      <phone>206-484-8830</phone>
      <email>snattam@fwmoh.com</email>
    </contact>
    <investigator>
      <last_name>Sreenivasa R. Nattam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel A. Vaena</last_name>
      <phone>319-356-2757</phone>
      <email>daniel-vaena@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel A. Vaena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arif Hussain</last_name>
      <phone>410-328-7225</phone>
      <email>ahussain@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Arif Hussain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajjai S. Alva</last_name>
      <phone>734-936-0091</phone>
      <email>ajjai@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ajjai S. Alva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulka N. Vaishampayan</last_name>
      <phone>313-576-8715</phone>
      <email>vaishamu@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ulka N. Vaishampayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Erlichman</last_name>
      <phone>507-266-3200</phone>
      <email>erlichman.charles@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Erlichman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro-Minnesota CCOP</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel M. Anderson</last_name>
      <phone>651-254-3572</phone>
      <email>jennik@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Daniel M. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Picus</last_name>
      <phone>314-362-5740</phone>
      <email>jpicus@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Joel Picus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark N. Stein</last_name>
      <phone>732-235-6031</phone>
      <email>steinmn@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Mark N. Stein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chandra P. Belani</last_name>
      <phone>717-531-1078</phone>
      <email>cbelani@psu.edu</email>
    </contact>
    <investigator>
      <last_name>Chandra P. Belani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul A. Parikh</last_name>
      <phone>412-648-6466</phone>
      <email>parikhr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul A. Parikh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Puzanov</last_name>
      <phone>615-936-6398</phone>
      <email>igor.puzanov@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Igor Puzanov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nizar M. Tannir</last_name>
      <phone>713-563-6969</phone>
      <email>ntannir@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Nizar M. Tannir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Swainey</last_name>
      <phone>804-828-9723</phone>
      <email>cswainey@mcvh-vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Swainey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle L. Harrison</last_name>
      <phone>02-9515-5494</phone>
      <email>Michelle.Harrison@sswahs.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Michelle L. Harrison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia-Chi (Josh) Lin</last_name>
      <phone>886-2-23123456 ext 67680</phone>
      <email>cclin1@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Chia-Chi (Josh) Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Democratic People's Republic of</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>November 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
